Trial Outcomes & Findings for Efficacy of Pimozide Augmentation for Clozapine Partial Response (NCT NCT00374244)

NCT ID: NCT00374244

Last Updated: 2016-03-04

Results Overview

The Brief Psychiatric Rating Scale (BPRS) is an 18-item instrument. The items are anchored on a 7-point scale (higher rating: greater severity). Total scores range from 18 to 126 (higher score: greater severity). The instrument covers areas including: somatic concerns, anxiety, emotional withdrawal, conceptual disorganization, guilt feelings, tension, mannerisms and posturing, grandiosity, depressive mood, hostility, suspiciousness, hallucinatory behavior, motor retardation, uncooperativeness, unusual thought content, blunted affect, excitement and disorientation.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

28 participants

Primary outcome timeframe

Baseline

Results posted on

2016-03-04

Participant Flow

This clinical trial was conducted at the outpatient clinics of the West Haven VA, Connecticut Mental Health Center of Yale Department of Psychiatry, and the Zucker-Hillside Hospital of Long Island Jewish Health Care System, and approved by the respective Institutional Review Boards.

Prior to randomization, a stable dose of clozapine for the past 2 weeks with a blood level of at least 350 ng/ml was targeted. Subjects were stratified as to whether they were receiving psychoactive medications such as mood stabilizers, to ensure that about equal numbers of subjects were randomized based on this treatment profile.

Participant milestones

Participant milestones
Measure
Placebo Pimozide
Half of the subjects were randomized to placebo group.
Active Pimozide
Half of the subjects are randomized to the active drug.
Overall Study
STARTED
14
14
Overall Study
COMPLETED
14
14
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Efficacy of Pimozide Augmentation for Clozapine Partial Response

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Placebo Pimozide
n=14 Participants
Half of the subjects were randomized to placebo group.
Active Pimozide
n=14 Participants
Half of the subjects are randomized to the active drug.
Total
n=28 Participants
Total of all reporting groups
Age, Continuous
41.5 years
STANDARD_DEVIATION 2.8 • n=99 Participants
44.3 years
STANDARD_DEVIATION 2.0 • n=107 Participants
43.0 years
STANDARD_DEVIATION 9.0 • n=206 Participants
Sex: Female, Male
Female
4 Participants
n=99 Participants
4 Participants
n=107 Participants
8 Participants
n=206 Participants
Sex: Female, Male
Male
10 Participants
n=99 Participants
10 Participants
n=107 Participants
20 Participants
n=206 Participants

PRIMARY outcome

Timeframe: Baseline

Population: Subjects were analyzed intent to treat.

The Brief Psychiatric Rating Scale (BPRS) is an 18-item instrument. The items are anchored on a 7-point scale (higher rating: greater severity). Total scores range from 18 to 126 (higher score: greater severity). The instrument covers areas including: somatic concerns, anxiety, emotional withdrawal, conceptual disorganization, guilt feelings, tension, mannerisms and posturing, grandiosity, depressive mood, hostility, suspiciousness, hallucinatory behavior, motor retardation, uncooperativeness, unusual thought content, blunted affect, excitement and disorientation.

Outcome measures

Outcome measures
Measure
Placebo Pimozide
n=14 Participants
Half of the subjects were randomized to placebo group.
Active Pimozide
n=14 Participants
Half of the subjects are randomized to the active drug.
Brief Psychiatric Rating Scale (BPRS) Total Score
44.1 units on a scale
Standard Error 2.0
44.3 units on a scale
Standard Error 2.0

PRIMARY outcome

Timeframe: Endpoint (12 weeks)

Population: Subjects were analyzed intent to treat.

The Brief Psychiatric Rating Scale (BPRS) is an 18-item instrument. The items are anchored on a 7-point scale (higher rating: greater severity). Total scores range from 18 to 126 (higher score: greater severity). The instrument covers areas including: somatic concerns, anxiety, emotional withdrawal, conceptual disorganization, guilt feelings, tension, mannerisms and posturing, grandiosity, depressive mood, hostility, suspiciousness, hallucinatory behavior, motor retardation, uncooperativeness, unusual thought content, blunted affect, excitement and disorientation.

Outcome measures

Outcome measures
Measure
Placebo Pimozide
n=14 Participants
Half of the subjects were randomized to placebo group.
Active Pimozide
n=14 Participants
Half of the subjects are randomized to the active drug.
Brief Psychiatric Rating Scale (BPRS) Total Score
37.9 units on a scale
Standard Error 2.1
39.6 units on a scale
Standard Error 2.1

PRIMARY outcome

Timeframe: baseline

Population: Analyzed intent to treat.

The Scale for the Assessment of Negative Symptoms (SANS) is a rating scale to measure negative symptoms in schizophrenia. The scale has 25 items (20 individual and 5 global) rated on scale of 0-5 (higher rating: greater severity). SANS is split into 5 domains, and within each domain separate symptoms are rated from 0 (absent) to 5 (severe). Domains include: Affective Flattening or Blunting, Alogia, Avolition - Apathy, Anhedonia - Asociality, Attention. The total range of the SANS is from 0 to 120.

Outcome measures

Outcome measures
Measure
Placebo Pimozide
n=14 Participants
Half of the subjects were randomized to placebo group.
Active Pimozide
n=14 Participants
Half of the subjects are randomized to the active drug.
Scale for the Assessment of Negative Symptoms (SANS)
44.3 units on a scale
Standard Error 5.9
38.5 units on a scale
Standard Error 5.8

PRIMARY outcome

Timeframe: Endpoint (12 weeks)

Population: Analyzed intent to treat.

The Scale for the Assessment of Negative Symptoms (SANS) is a rating scale to measure negative symptoms in schizophrenia. The scale has 25 items (20 individual and 5 global) rated on scale of 0-5 (higher rating: greater severity). SANS is split into 5 domains, and within each domain separate symptoms are rated from 0 (absent) to 5 (severe). Domains include: Affective Flattening or Blunting, Alogia, Avolition - Apathy, Anhedonia - Asociality, Attention. The total range of the SANS is from 0 to 120.

Outcome measures

Outcome measures
Measure
Placebo Pimozide
n=14 Participants
Half of the subjects were randomized to placebo group.
Active Pimozide
n=14 Participants
Half of the subjects are randomized to the active drug.
Scale for the Assessment of Negative Symptoms (SANS)
36.3 units on a scale
Standard Error 5.9
37.3 units on a scale
Standard Error 5.9

SECONDARY outcome

Timeframe: baseline

Population: Analyzes intent to treat.

CGI Severity of Illness Scale (CGI-S) assesses severity of illness on 1-7 scale. Clinicians' experience is used to gauge the severity of illness from 'normal' (value=1) to 'among the most extremely ill patients' (value=7). The higher rating correlates with more severely ill.

Outcome measures

Outcome measures
Measure
Placebo Pimozide
n=14 Participants
Half of the subjects were randomized to placebo group.
Active Pimozide
n=14 Participants
Half of the subjects are randomized to the active drug.
CGI Severity of Illness Scale (CGI-S)
4.1 units on a scale
Standard Error 0.5
4.0 units on a scale
Standard Error 0.9

SECONDARY outcome

Timeframe: Endpoint (12 weeks)

Population: Analyzed intent to treat.

CGI Severity of Illness Scale (CGI-S) assesses severity of illness on 1-7 scale. Clinicians' experience is used to gauge the severity of illness from 'normal' (value=1) to 'among the most extremely ill patients' (value=7). The higher rating correlates with more severely ill.

Outcome measures

Outcome measures
Measure
Placebo Pimozide
n=14 Participants
Half of the subjects were randomized to placebo group.
Active Pimozide
n=14 Participants
Half of the subjects are randomized to the active drug.
CGI Severity of Illness Scale (CGI-S)
3.9 units on a scale
Standard Error 0.8
3.9 units on a scale
Standard Error 0.5

SECONDARY outcome

Timeframe: Endpoint (12 weeks)

Population: Analyzed intent to treat.

CGI Improvement Scale (CGI-I) higher rating correlates with worsening of condition (vs. improvement with lower rating). The CGI-I is scored from 1 to 7 where 1 = 'very much improved' and 7 = 'very much worse'. Clinicians are asked to rate total improvement in the following manner: "...in your judgement, it is due entirely to drug treatment. Compared to his condition at admission to the project, how much has he changed?"

Outcome measures

Outcome measures
Measure
Placebo Pimozide
n=14 Participants
Half of the subjects were randomized to placebo group.
Active Pimozide
n=14 Participants
Half of the subjects are randomized to the active drug.
CGI Improvement Scale (CGI-I)
2.8 units on a scale
Standard Error 1.0
3.4 units on a scale
Standard Error 0.5

SECONDARY outcome

Timeframe: Baseline

Population: Intent to Treat Analysis

Verbal fluency was measured using the Controlled Word Association Test (COWAT). There is no range for this measure, as it is not a scale. The subjects can generate as many new words as they can, so there is no maximum. The greater the number of words one generates indicates better performance.

Outcome measures

Outcome measures
Measure
Placebo Pimozide
n=14 Participants
Half of the subjects were randomized to placebo group.
Active Pimozide
n=14 Participants
Half of the subjects are randomized to the active drug.
Verbal Fluency
12.2 words
Standard Deviation 1.4
10.5 words
Standard Deviation 1.5

SECONDARY outcome

Timeframe: Endpoint (12 weeks)

Population: Intent to Treat Analysis

Verbal fluency was measured using the Controlled Word Association Test (COWAT). There is no range for this measure, as it is not a scale. The subjects can generate as many new words as they can, so there is no maximum. The greater the number of words one generates indicates better performance.

Outcome measures

Outcome measures
Measure
Placebo Pimozide
n=14 Participants
Half of the subjects were randomized to placebo group.
Active Pimozide
n=14 Participants
Half of the subjects are randomized to the active drug.
Verbal Fluency
12.3 words
Standard Deviation 1.5
11.1 words
Standard Deviation 1.5

SECONDARY outcome

Timeframe: Baseline

Population: Intention to Treat

The QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart. ECG machines calculate a corrected QT (QTc). QTc is the corrected QT interval in the EKG. Normal range is from 430-470ms.

Outcome measures

Outcome measures
Measure
Placebo Pimozide
n=14 Participants
Half of the subjects were randomized to placebo group.
Active Pimozide
n=14 Participants
Half of the subjects are randomized to the active drug.
QTc
408.8 ms
Standard Deviation 5.0
412.3 ms
Standard Deviation 5.1

SECONDARY outcome

Timeframe: Endpoint (12 weeks)

Population: Intention to Treat

The QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart. ECG machines calculate a corrected QT (QTc). QTc is the corrected QT interval in the EKG. Normal range is from 430-470ms.

Outcome measures

Outcome measures
Measure
Placebo Pimozide
n=14 Participants
Half of the subjects were randomized to placebo group.
Active Pimozide
n=14 Participants
Half of the subjects are randomized to the active drug.
QTc
412.9 ms
Standard Deviation 5.0
420.3 ms
Standard Deviation 5.2

SECONDARY outcome

Timeframe: Baseline

Population: Intent to Treat Analysis

Processing speed was assessed using using Digit Symbol Coding from the Wechsler Adult Intelligence Scale, Revised (WAIS-R). The tool is used for the assessment of processing speed. The range of scores is 0 to 100- with the higher number indicating greater performance.

Outcome measures

Outcome measures
Measure
Placebo Pimozide
n=14 Participants
Half of the subjects were randomized to placebo group.
Active Pimozide
n=14 Participants
Half of the subjects are randomized to the active drug.
Processing Speed
48.8 units on a scale
Standard Deviation 4.6
43.3 units on a scale
Standard Deviation 4.9

SECONDARY outcome

Timeframe: Endpoint (12 weeks)

Population: Intent to Treat Analysis

Processing speed was assessed using using Digit Symbol Coding from the Wechsler Adult Intelligence Scale, Revised (WAIS-R). The tool is used for the assessment of processing speed. The range of scores is 0 to 100- with the higher number indicating greater performance.

Outcome measures

Outcome measures
Measure
Placebo Pimozide
n=14 Participants
Half of the subjects were randomized to placebo group.
Active Pimozide
n=14 Participants
Half of the subjects are randomized to the active drug.
Processing Speed
46.5 units on a scale
Standard Deviation 4.7
42.8 units on a scale
Standard Deviation 5.0

SECONDARY outcome

Timeframe: Baseline

Population: Intent to Treat Analysis

Verbal learning and memory were assessed by the Rey Auditory Verbal Learning Test (RAVLT) List A: Total Trials (1-5). This assessment consists of a list of words that the subject repeats back, it does not have an interpret-able range of scores like a traditional scale. Scores are based on number of words repeated back.

Outcome measures

Outcome measures
Measure
Placebo Pimozide
n=14 Participants
Half of the subjects were randomized to placebo group.
Active Pimozide
n=14 Participants
Half of the subjects are randomized to the active drug.
Verbal Learning and Memory: List A
40.0 words
Standard Deviation 3.3
26.5 words
Standard Deviation 2.8

SECONDARY outcome

Timeframe: Endpoint (12 weeks)

Population: Intent to Treat Analysis

Verbal learning and memory were assessed by the Rey Auditory Verbal Learning Test (RAVLT) List A: Total Trials (1-5). This assessment consists of a list of words that the subject repeats back, it does not have an interpret-able range of scores like a traditional scale. Scores are based on number of words repeated back.

Outcome measures

Outcome measures
Measure
Placebo Pimozide
n=14 Participants
Half of the subjects were randomized to placebo group.
Active Pimozide
n=14 Participants
Half of the subjects are randomized to the active drug.
Verbal Learning and Memory: List A
38.0 words
Standard Deviation 4.8
32.3 words
Standard Deviation 4.2

SECONDARY outcome

Timeframe: Baseline

Population: Intent to Treat Analysis

Verbal learning and memory were assessed by the Rey Auditory Verbal Learning Test (RAVLT) List B: Single Trial. This assessment consists of a list of words that the subject repeats back, it does not have an interpret-able range of scores like a traditional scale. Scores are based on number of words repeated back.

Outcome measures

Outcome measures
Measure
Placebo Pimozide
n=14 Participants
Half of the subjects were randomized to placebo group.
Active Pimozide
n=14 Participants
Half of the subjects are randomized to the active drug.
Verbal Learning and Memory: List B
3.8 words
Standard Deviation 0.4
3.5 words
Standard Deviation 0.4

SECONDARY outcome

Timeframe: Endpoint (12 weeks)

Population: Intent to Treat Analysis

Verbal learning and memory were assessed by the Rey Auditory Verbal Learning Test (RAVLT) List B: Single Trial. This assessment consists of a list of words that the subject repeats back, it does not have an interpret-able range of scores like a traditional scale. Scores are based on number of words repeated back.

Outcome measures

Outcome measures
Measure
Placebo Pimozide
n=14 Participants
Half of the subjects were randomized to placebo group.
Active Pimozide
n=14 Participants
Half of the subjects are randomized to the active drug.
Verbal Learning and Memory: List B
3.4 words
Standard Deviation 0.6
3.9 words
Standard Deviation 0.6

SECONDARY outcome

Timeframe: Baseline

Population: Intent to Treat Analysis

Working memory by Digit Span and Letter Number Sequencing, and attention/executive functions were measured by the Trail Making Test (Parts A and B). This is an assessment of attention/executive function, it does not have an interpret-able range of scores like a traditional scale. Subjects makes trails on paper against time.

Outcome measures

Outcome measures
Measure
Placebo Pimozide
n=14 Participants
Half of the subjects were randomized to placebo group.
Active Pimozide
n=14 Participants
Half of the subjects are randomized to the active drug.
Trail Making Test: Trail A
3.7 seconds
Standard Deviation 0.1
3.8 seconds
Standard Deviation 0.1

SECONDARY outcome

Timeframe: Endpoint (12 weeks)

Population: Intent to Treat Analysis

The Trail Making Test is a neuropsychological test of visual attention and task switching. It consists of two parts in which the subject is instructed to connect a set of 25 dots as fast as possible while still maintaining accuracy. ( Arnett, James A.; Seth S. Labovitz (1995). "Effect of physical layout in performance of the Trail Making Test". Psychological Assessment 7 (2): 220-221. doi:10.1037/1040-3590.7.2.220. Retrieved 2012-02-22.) Part A is used primarily to examine cognitive processing speed. Part B, in which the subject alternates between numbers and letters, is used to examine executive functioning. (Tombaugh, T.N.T.N (2004). "Trail Making test A and B: Normative Data Stratified by Age and Education". Archives of Clinical Neuropsychology : The Official Journal of the National Academy of Neuropsychologists 19 (2): 203-214. doi:10.1016/s0887-6177(03)00039-8. Retrieved 2012-01-10.)

Outcome measures

Outcome measures
Measure
Placebo Pimozide
n=14 Participants
Half of the subjects were randomized to placebo group.
Active Pimozide
n=14 Participants
Half of the subjects are randomized to the active drug.
Trail Making Test: Trail A
3.6 seconds
Standard Deviation 0.1
3.8 seconds
Standard Deviation 0.1

SECONDARY outcome

Timeframe: Baseline

Population: Intent to Treat Analysis

The Trail Making Test is a neuropsychological test of visual attention and task switching. It consists of two parts in which the subject is instructed to connect a set of 25 dots as fast as possible while still maintaining accuracy. ( Arnett, James A.; Seth S. Labovitz (1995). "Effect of physical layout in performance of the Trail Making Test". Psychological Assessment 7 (2): 220-221. doi:10.1037/1040-3590.7.2.220. Retrieved 2012-02-22.) Part A is used primarily to examine cognitive processing speed. Part B, in which the subject alternates between numbers and letters, is used to examine executive functioning. (Tombaugh, T.N.T.N (2004). "Trail Making test A and B: Normative Data Stratified by Age and Education". Archives of Clinical Neuropsychology : The Official Journal of the National Academy of Neuropsychologists 19 (2): 203-214. doi:10.1016/s0887-6177(03)00039-8. Retrieved 2012-01-10.)

Outcome measures

Outcome measures
Measure
Placebo Pimozide
n=14 Participants
Half of the subjects were randomized to placebo group.
Active Pimozide
n=14 Participants
Half of the subjects are randomized to the active drug.
Trail Making Test: Trail B
4.6 seconds
Standard Deviation 0.2
4.9 seconds
Standard Deviation 0.2

SECONDARY outcome

Timeframe: Endpoint (12 weeks)

Population: Intent to Treat Analysis

The Trail Making Test is a neuropsychological test of visual attention and task switching. It consists of two parts in which the subject is instructed to connect a set of 25 dots as fast as possible while still maintaining accuracy. ( Arnett, James A.; Seth S. Labovitz (1995). "Effect of physical layout in performance of the Trail Making Test". Psychological Assessment 7 (2): 220-221. doi:10.1037/1040-3590.7.2.220. Retrieved 2012-02-22.) Part A is used primarily to examine cognitive processing speed. Part B, in which the subject alternates between numbers and letters, is used to examine executive functioning. (Tombaugh, T.N.T.N (2004). "Trail Making test A and B: Normative Data Stratified by Age and Education". Archives of Clinical Neuropsychology : The Official Journal of the National Academy of Neuropsychologists 19 (2): 203-214. doi:10.1016/s0887-6177(03)00039-8. Retrieved 2012-01-10.)

Outcome measures

Outcome measures
Measure
Placebo Pimozide
n=14 Participants
Half of the subjects were randomized to placebo group.
Active Pimozide
n=14 Participants
Half of the subjects are randomized to the active drug.
Trail Making Test: Trail B
4.6 seconds
Standard Deviation 0.2
4.9 seconds
Standard Deviation 0.2

Adverse Events

Placebo Pimozide

Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths

Active Pimozide

Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Placebo Pimozide
n=14 participants at risk
Half of the subjects were randomized to placebo group.
Active Pimozide
n=14 participants at risk
Half of the subjects are randomized to the active drug.
Cardiac disorders
QTc Prolongation
7.1%
1/14 • Number of events 1
7.1%
1/14 • Number of events 1

Additional Information

Handan Gunduz-Bruce MD

Yale University School of Medicine, Dept of Psychiatry

Phone: (203) 932-5711

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place